Activation of peptide prodrugs by hK2
US8669231B2 · kind B2 · utility
0Cited by
5References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2011 |
| Grant date | Mar 11, 2014 |
| Priority date | — |
| Expiry date | Jun 6, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.